Abstract
Influenza is a well known infection of the respiratory system. The main clinical manifestations of influenza include fever, sore throat, headache, cough, coryza, and malaise. Apart from the well known classical influenza, there are also groups of influenza virus infections that are called “atypical infection”. These infections are usually due to a novel influenza virus infection. In early 2009, an emerging novel influenza originating from Mexico called swine flu was reported. The World Health Organization noted a level VI precaution, the highest level precaution possible, for this newest influenza virus infection. As of June 2009, it is not known if this disease will be successfully controlled. Finding new drugs and vaccine for the emerging swine flu is still required to cope with this emerging worldwide problem.
Influenza infection
Etiology
Influenza is a well known infection.Citation1,Citation2 It is classified as a respiratory system infection. The main pathogenic cause of influenza is virus. The influenza virus is a widely studied virus in medicine.Citation1,Citation2 As a respiratory tract infection, the influenza virus is mainly transmitted via air as an airborne infectious disease.Citation1,Citation2 The pathogenic influenza virus can enter into the human body due to the inhalation of infectious air particles.Citation3,Citation4 The contaminated airborne particles can be generated by sneezing and coughing by infected patients.Citation3,Citation4 Specific body secretions that are highly contaminated with influenza virus include running nose fluids and saliva. It should also be noted that contaminated secretions can be found in spillage and in any used objects for up to two hours.Citation3,Citation4 If someone contacts the contaminated object, there is a possibility of infection and transmission of pathogen can be expected. Recently, Grayson and colleagues said that soap and water hand-washing or alcohol-based hand rub was highly effective in reducing influenza virus on human hands.Citation15 Hand washing is an important practice to control the spread of influenza.Citation5–Citation8
Clinical manifestations
In general, influenza virus can be classified into three main groups, group A, group B, and group C.Citation9,Citation10 All groups can cause disease in human beings. Only group A can also cause infection in animals. Generally, patients usually develop signs and symptoms within two days (range 1–4 days) after contact with the pathogen.Citation11,Citation12 However, the isolation of influenza virus may not be seen, hence, transmission of disease can be possible before signs and symptoms are manifested.Citation11,Citation12 The peak of fever can be usually seen in day 3.Citation11,Citation12 The main clinical manifestations of influenza include fever, sore throat, headache, cough, coryza, and malaise. Due to the nature of the virus, the course of illness usually completes within one week or on day 9 after the first contact with the pathogen. Influenza complications usually start after this period.Citation13 In general, the disease burden due to influenza is usually low.Citation14,Citation15 Hospitalization is usually required for two specific age groups: the infant group aged less than six months and the elderly group aged more than 65 years. Factors relating to the severity of influenza include age and underlying personal illness. The high-risk population for severe clinical manifestation includes the elder group aged more than 65 years,Citation16 the infant group aged less than two years,Citation17 patients with human immunodeficiency virus (HIV) infection,Citation18 patients with chronic obstructive pulmonary disease and asthma,Citation19 patients with congenital heart disease,Citation20 patients on immunosuppressive drugs, and patients with prolonged usage of aspirin.
In the general low-risk adult population, the signs and symptoms of influenza can be self-limited. There is no need for medication. Serious complicationsCitation21,Citation22 can be seen, such as otitis media, pneumonitis,Citation23 myocarditis,Citation24 encephalopathy,Citation25,Citation26 and Reye’s syndrome.Citation27 As previously noted, the prevalence of complication is high in the at-risk groups.Citation21,Citation22 For example, up to 10% of infantile cases can develop complications and can end up with influenza encephalopathy. The rate of fatality in influenza encephalopathy is as high as one third of affected cases.Citation25,Citation26
Diagnosis, treatment, and prevention
Clinical diagnosis is generally used for presumptive diagnosis. However, the main problem is due to the similarity between influenza and other respiratory tract infections. Laboratory investigation is required to confirm diagnosis. The basic immunological diagnosis is useful.Citation28–Citation38 However, a molecular-based diagnostic tool is usually required in atypical cases.Citation39–Citation45 This is because although the immunology-based technique is cheaper and faster in diagnosis, it lacks specificity. New molecular-based diagnostic tools can provide the most specific result since the diagnosis is based on the exact sequence of the viral particle. However, molecular-based diagnosis is expensive and time-consuming to perform. Therefore it might be unavailable and unaffordable for poor settings in developing countries.
Since the influenza viral infection can be self-limiting in otherwise healthy adults, there is no need for specific medication or treatment.Citation46 However, in at-risk cases, an antiviral drug treatment is recommended.Citation46–Citation50 The widely used antiviral drugs for influenza are amantadine,Citation51 rimantadine,Citation52 oseltamivir,Citation53 and zanamivir.Citation54–Citation56 Oseltamivir and zanamivir are newer drugs with a lower drug-resistant rate. These two drugs are also indicated for atypical cases.
At present, a specific influenza vaccine is available for prevention and is recommended for the at-risk population, especially the elderly.Citation57,Citation58 Jefferson and colleagues noted in a Cochrane review that influenza vaccines were effective in reducing cases of influenza, but were less effective in reducing cases of influenza-like illness.Citation59 Jefferson and colleagues also noted that influenza vaccines had a modest impact on lost working days but there was no sufficient evidence on complications.Citation59 In the scenario of an influenza pandemic, vaccination is the main hope for disease control.Citation60
Novel influenza virus infection: What is it?
Apart from the already mentioned classical influenza virus infection, there are also a group of influenza virus infections that are called “atypical infection”. These infections are usually due to a novel influenza virus infection.Citation61,Citation62 Those new pathogenic viruses, which usually result from genetic mutations, correspond to atypical infection. The new infection is usually recognized as a new emerging infectious disease.Citation63
Zoonosis is usually mentioned for any novel influenza virus infection. “Why is zoonosis usually mentioned?” is an interesting question. As previously noted, influenza group A can infect both human beings and animals. When animals live near human beings, the exchange of viruses that each side carries can be expected and the final result can be a new, emerging zoonosis. This viral transmission scenario is a big problem for medicine since new emerging infections are new diseases that human beings have never experienced before.
The lack of immunity can be seen since present data indicate that only some older individuals have immunity against the current novel influenza A (H1N1).Citation64 At present, most physicians are already aware of this ongoing pandemic.
Examples of emerging influenza are well known. The case of avian fluCitation65–Citation71 which emerged in the few recent years is the best example (). Avian flu is a novel influenza virus infection (owing to H5N1 influenza virus infection). This bird-borne disease is still a problem worldwide.Citation65–Citation72 No specific treatment has been developed yet. Luckily, only sporadic cases occurred around the world without pandemic. However, another emerging novel influenza originated from Mexico in early 2009.Citation73–Citation85 This new infection is called swine flu (). Swine flu is caused by the novel influenza virus, H1N1 influenza virus. The novel H1N1 influenza virus that causes swine flu is the result from genetic reassortment of gene segments from not only human H1N1 virus, but North American swine flu, Asian swine flu, and avian flu.Citation87 This new recombinant virus causes the current pandemic and leads to generalized infection worldwide.Citation85 In early June 2009, the swine flu, which is now called influenza 2009 is pandemic in many countries worldwide (more than 70 countries and more than 25,000 infected cases).Citation85 The World Health Organization (WHO) noted a level VI precaution, the highest level precaution possible, for this newest influenza virus infection (). As of June 2009, it is not known if this disease will be successfully controlled. Finding new drugs and vaccine for emerging swine flu is still required to cope with this emerging problem worldwide. This review focuses on the search for new drugs and a vaccine for swine flu. Data from searching all available publications from PubMed, Scopus, and ISI databases were included, and non-English language papers were excluded.
Table 1 Details of important novel influenza
Table 2 Summary of some problematic points of swine flu infection Citation73–Citation85
Concepts on finding new drug for swine flu
As previously noted, swine flu is an emerging disease. Treatments for swine flu are suggested and the general practice guideline for dealing with influenza is applied (). A routine antiviral for influenza is applied. Since amantadine and rimantadine are confirmed for drug-resistant strains of influenza,Citation88–Citation90 the recommended drugs are oseltamivir and zanamivir. In current general practice (), oseltamivir is routinely used in cases with swine flu with good efficacy.Citation88–Citation90 Focusing on the pharmacological reaction, oseltamivir blocks the M2 protein and blocks viral penetration and uncoating.Citation91,Citation92 According to an US report, no resistance to oseltamivir in the emerging swine flu was observed.Citation88–Citation90
Table 3 Presently available antiviral drugs for influenza treatment
Table 4 Recommended dosage of oseltamivir and zanamivir in treatment and prevention for swine flu (adapted from World Health Organization recommendations, see http://www.cdc.gov/swineflu/recommendation.htm)
However, new drugs for swine flu need to be sought. This need is due to several reasons. First, although oseltamivir is still effective, drug resistance is expected to develop in the near future due to a high volume of use in the pandemic scenario. Second, we can expect a genetic instability in the swine flu virus. In addition to new drugs, there is also a need for the local production of generic drugs of oseltamivir in developing countries. This issue needs to be carefully considered as drug patent concerns may be an obstacle for the local production of oseltamivir in many developing countries.
As previously mentioned, this paper will focus in the pharmacological dynamic issue of drug development and this paper does not discuss the current treatment process of swine flu. In order to find new drugs for swine flu, the recommended steps are listed below:
The viral sequence of the novel influenza virus must be mapped. Luckily, plenty of data are already loaded into public databases such as PubMed. At present, a diagnostic tool with real-time polymerase chain reaction (PCR) for influenza A is available and recommended as a diagnostic test by the US Food and Drug Administration (FDA). This provided several data on the genomics of the new emerging virus and helps further clarifies its viral structure. The data on sequence and structure of swine flu are useful not only for drug development, but also for diagnostic tool development.
The next focus should be on proven drugs. The reaction between the presently used drug, oseltamivir, and swine flu virus has to be clarified. This reaction has to be shown at the molecular level. Study by crystallization technique is suggested. Simulation by a molecular-docking technique can be helpful at this point. There are some present researches on this stage.Citation93,Citation94 According to the homology modeling of the neuraminidase, it can be seen that novel mutations are not likely to interfere with the active site hence the currently used neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) will still be effective against the new virus strain.Citation94 The same mechanism of pharmacological reaction, blocking M2, can be seen in either classical or novel viruses. However, the drugs do not have the same effect in both viruses. This might be explained by the difference in required energy for drug–virus binding reaction.Citation92 More required energy can be seen in case of the novel H1N1 influenza virus, which, based on the new viral genomic sequence, is larger than that of the classical virus.Citation92
Possible genetic variation at the reaction site should also be predicted. This is useful for further calculation on optimum pharmacological binding energy between antiviral drug and virus. The mutated resistant portion should be the specific favorable site for our pharmacological target. Although a big genetic shift of the new virus has not yet been reported, it can be expected. Modification of previously used drugs into new drugs can be done based on the described data.
The derived drug needs to be tested in vitro and in vivo with a special focus on possible adverse effects including toxicity, mutagenesis, teratogenesis, and carcinogenesis. All drugs must pass and follow WHO recommendations with the four complete drug trial stages before becoming commercially available. This is needed to confirm that the drug is actually effective and pose no unwanted adverse effects.
Concepts on finding new vaccine for swine flu
Although there are several measures for prevention for swine flu including basic sanitation practice (hand-washing and mask use), isolation, chemoprophylaxis, and vaccination, vaccination is expected to be the most effective tool. Although there is evidence on the finding of immunity to the new virus in some elderly adults,Citation63 this might be a cross-protective immunity since there are some antigenic similarities to currently or previously circulating strains of influenza.Citation94 There is currently no effective vaccine for swine flu. The classical influenza vaccine is not applicable. Finding a new vaccine for swine flu is the current hot topic in medicine.Citation95 The current question is how to produce an effective pandemic influenza vaccine.Citation96,Citation97 Focusing on classical influenza, the problem of the genetic shift highlights the problem of the efficacy of the in-use influenza vaccine. In the case of the novel influenza swine flu, the problem remains. For production of pandemic influenza vaccine, the similar process to that of seasonal (regular) influenza vaccine can be followed. Nevertheless, adding to the basic two major focuses, safety and efficacy, for seasonal influenza vaccine, the other two major focuses, immunogenicity and timely availability, are also needed for pandemic influenza vaccine.Citation94,Citation95 However, the original seed virus must be the new virus. This raises the problem of production because it is hard to make the new virus available in huge amounts. The problem might be solved by present biotechnology, but the limitation of technology in developing countries also prevents success in local production of new vaccine in those settings. There are also post-production concerns: “How to test the new vaccine in the shortest period?” “How to register the new vaccine in each country?” “How to administer the vaccine to the at-risk population in each country?”
To find a new vaccine for swine flu, the recommended steps are listed below:
It will be necessary to completely map the genome of the novel influenza virus. This is the main requirement because any new vaccine has to be based on the genomic information of the new virus. Luckily, this data is presently available. The genomics data of the novel influenza virus is freely available on public databases such as PubMed.Citation87 According to the recent study by Maurer-Stroh and colleagues, the antigenic regions of the neuraminidase relevant for vaccine development, serological typing, and passive antibody treatment was totally different from those of classical influenza.Citation94 This is the main reason for asking why the vaccine for classical influenza cannot be applied for the novel strain and this is also the reason for the need for finding a new vaccine specific to the novel virus.
The immunological aspect of the new emerging virus must be known by finding the immunogenic part of the new virus. The use of immunomics technology might help shorten this period. The finding of the epitope is the basic primary step to find a new vaccine.
The application of new recombinant biotechnology to produce sufficient amount of new original seed virus for production of pandemic influenza vaccine must be completed.Citation92,Citation93
Post-production testing to assess both safety and efficacy of the derived vaccine is required. On one hand, the new vaccine has to be well verified before real world use. On the other hand, this process has to be as fast as possible to cope with the fast emerging pandemic.
Post-marketing surveillance to follow up the effectiveness and adverse effect of the new vaccine is needed, similar to the routine practice for all new vaccines.
As already noted, a new vaccine has just been manufactured and approved by the US FDA.Citation86 However, it should be noted that there is still no report on the clinical and epidemiological aspect of the new vaccine is only in the trial phase. It is not possible to present the data on these aspects in this review. This information will be provided by future studies.
Disclosure
The author reports no conflicts of interest in this work.
References
- StamboulianDBonvehíPENacinovichFMCoxNInfluenzaInfect Dis Clin North Am200014114116610738677
- TurkulovVMadle-SamardzijaNInfluenza – always present among usMed Pregl2000533–415415810965680
- GapochkoKGOgarkovVIExperimental production of air-borne infectionsZh Mikrobiol Epidemiol Immunobiol1972491184924347310
- TatemAJRogersDJHaySIGlobal transport networks and infectious disease spreadAdv Parasitol20066229334316647974
- GraysonMLMelvaniSDruceJEfficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteersClin Infect Dis200948328529119115974
- SimberkoffMSSantosMRPrevention of community-acquired and nosocomial pneumoniaCurr Opin Pulm Med1996232282359363144
- American Academy of Pediatrics Committee on Infectious DiseasesInfection prevention and control in pediatric ambulatory settingsPediatrics2007120365066517766540
- CarterJMHand washing decreases risk of colds and fluJ Natl Med Assoc2002942A11
- MaedaYHorimotoTKawaokaYClassification and genome structure of influenza virusNippon Rinsho200361111886189114619426
- JuozapaitisMAntoniukasLInfluenza virusMedicina (Kaunas)2007431291992918182834
- DowdleWRColemanMTGreggMBNatural history of influenza type A in the United States, 1957–1972Prog Med Virol197417911354608959
- RobinsonRQNatural history of influenza since the introduction of the A2 strainProg Med Virol196468211014310577
- CoxNJSubbaraoKInfluenzaLancet199935491861277128210520648
- Easing the burden: the challenge of managing influenzaAm J Manag Care200065 SupplS276S28110977474
- GaussetMFCasadebaigFGuillaud-BatailleJMQuemadaNTerraJLMortality of mentally ill patients. Review of the literatureEncephale1992181931001600896
- YoshikawaTTImportant infections in elderly personsWest J Med198113564414457039132
- WestcarSChantlerTInfluenza: an overview with a paediatric focusCommunity Pract20078012373918186365
- AlagiriswamiACheesemanSHInfluenza and HIV: case report and review of potential interactionsAIDS Patient Care STDS2001151156156511788065
- FerdinandsJMManninoDMObstructive lung disease models: what is valid?COPD20085638239319353353
- LansdownABViral Infections and diseases of the heartProg Med Virol19782470113360296
- RothbergMBHaesslerSDBrownRBComplications of viral influenzaAm J Med2008121425826418374680
- Bro-J⊘rgensenKSamuelssonISInfluenza. Consequences for health and preventionUgeskr Laeger198915140257025742683282
- RubenFLCateTRInfluenza pneumoniaSemin Respir Infect1987221221293321270
- SanoTInfluenza myocarditis and pericarditisNippon Rinsho200664101916192017037367
- Moreno-FlaggeNBayardVQuirósEAlonsoTAcute encephalitis. Neuropsychiatric manifestations as expression of influenza virus infectionMedicina (B Aires)200969112112619240010
- NobusawaEInfluenza encephalopathy and encephalitisNo To Hattatsu200032214214710723190
- WehingerHReye syndrome (author’s transl)Klin Padiatr19771893206210327146
- SullivanCJJordanMCDiagnosis of viral pneumoniaSemin Respir Infect1988321481612840725
- FlewettTHRapid diagnosis of virus diseasesBr Med Bull19854143153212996682
- Chai kaNAGorbachevENUse of the sensitized latex agglutination reaction for diagnosing viral infectionsVopr Virusol19853055165233000079
- TurnerPARytelMWDiagnosis and management of viral infectionsCompr Ther198410620296203680
- VollerABidwellDEBartlettAELISA techniques in virologyLab Res Methods Biol Med1982559816281599
- FrankALSelected laboratory aspects of influenza surveillanceYale J Biol Med1982553–42012056758369
- SchmidtJBrunnemannHStelznerASüssJKittlickMOehringHVirological diagnostics of acute respiratory diseasesZ Erkr Atmungsorgane1980154118357001774
- OswaldNCJonesMCYeallandSJA review of routine tests for respiratory viruses in hospital inpatientsThorax1975304361366170701
- RytelMWRapid diagnostic methods in infectious diseasesAdv Intern Med1975203760803762
- HofmannHModern virus diagnosticsWien Med Wochenschr1973123497257294357782
- PereiraHGInfluenza: antigenic spectrumProg Med Virol19691146794906872
- MikhailovichVGryadunovDKolchinskyAMakarovAAZasedatelevADNA microarrays in the clinic: infectious diseasesBioessays200830767368218536036
- VernetGUse of molecular assays for the diagnosis of influenzaExpert Rev Anti Infect Ther2007518910417266457
- CiçekCBilgiçACurrent approaches to the clinical virologic diagnosis of viral respiratory tract infectionsMikrobiyol Bul2003372–319520414593903
- EllisJSZambonMCMolecular diagnosis of influenzaRev Med Virol200212637538912410529
- TakahashiHRecent progress in the diagnosis of respiratory disease: respiratory infectionRinsho Byori200048121130113511215422
- HuangLMRecent advances in the study, prevention, and treatment of infectious diseasesJ Formos Med Assoc2000992929910770022
- ShawMWArdenNHMaassabHFNew aspects of influenza virusesClin Microbiol Rev19925174921310439
- HarperSABradleyJSSeasonal influenza in adults and children – diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of AmericaClin Infect Dis20094881003103219281331
- ColmanPMNew antivirals and drug resistanceAnnu Rev Biochem2009789511819254207
- HaydenFDeveloping new antiviral agents for influenza treatment: what does the future hold?Clin Infect Dis200948Suppl 1S3S1319067613
- ColmanPMA novel approach to antiviral therapy for influenzaJ Antimicrob Chemother199944Suppl B172210877458
- LaustsenGWimettLDrug approval highlights for 2003Nurse Pract2004292815192114872168
- TakeuchiYAmantadineNippon Rinsho200361111967197414619440
- HannounCRimantadine in the prevention and treatment of influenza ARev Med Interne1988955545583067304
- SchirmerPHolodniyMOseltamivir for treatment and prophylaxis of influenza infectionExpert Opin Drug Saf20098335737119355841
- OxfordJSZanamivir (Glaxo Wellcome)Drugs200034447459
- CheerSMWagstaffAJSpotlight on zanamivir in influenzaAm J Respir Med20021214715214720068
- CaballeroEPrietoCRuizMAzanzaJRZanamivir: new therapeutic option for influenzaRev Med Univ Navarra2000441566111002900
- WiwanitkitVNew respiratory virus (chicken pox, influenza and respiratory syncytial virus) vaccines: Efficacy, necessity and policy for tropical world at presentHum Vaccin200959 [Epub ahead of print]
- JeffersonTDemicheliVInfluenza vaccination for elderly people and their care workersLancet200736995761857185817544759
- JeffersonTORivettiDDi PietrantonjCRivettiADemicheliVVaccines for preventing influenza in healthy adultsCochrane Database Syst Rev20072CD00126917443504
- AuewarakulPThongcharoenPVaccines for a potential influenza pandemicFuture Microbiol2007234534917661708
- ForgieSMarrieTJHealthcare-associated atypical pneumoniaSemin Respir Crit Care Med2009301678519199189
- KajiMInfluenza and other viral respiratory infectionsNippon Rinsho200361111880188514619425
- CherkasskiiBLNew infections: myths and realityZh Mikrobiol Epidemiol Immunobiol2007311111617672145
- JeeningaREde JongMDBerkhoutBThe New Influenza A (H1N1) PandemicJ Formos Med Assoc2009108752352519586824
- ChanPKA review on human influenza A H5N1 infections in Hong KongSci China C Life Sci200952541241819471863
- KhannaMKumarPChoudharyKKumarBVijayanVKEmerging influenza virus: a global threatJ Biosci200833447548219208973
- HolstPJChristensenJPThomsenARAvian influenza and perspectives on vaccination against pandemic influenzaUgeskr Laeger200824170(48)3953395619087735
- OngAKindhauserMSmithIChanMA global perspective on avian influenzaAnn Acad Med Singapore200837647748118618059
- LupianiBReddySMThe history of avian influenzaComp Immunol Microbiol Infect Dis200932431132318533261
- PappaioanouMHighly pathogenic H5N1 avian influenza virus: cause of the next pandemic?Comp Immunol Microbiol Infect Dis200932428730019318178
- GueryBGuidetBBeloucifSOrganization of intensive care in situation of avian flu pandemicArch Pediatr200815121781179318995996
- WiwanitkitVNo evidence of gynecological and obstetrical manifestation in H5N1 influenza virus infectionArch Gynecol Obstet2009279460919011883
- WiwanitkitVObstetrical concern on new emerging swine fluArch Gynecol Obstet2009524 [Epub ahead of print]
- NaffakhNvan der WerfSApril 2009: an outbreak of swine-origin influenza A(H1N1) virus with evidence for human-to-human transmissionMicrobes Infect2009118–972572819442755
- WangTTPalesePUnraveling the mystery of swine influenza virusCell2009137698398519524497
- WhileASwine flu: some good lessons learntBr J Community Nurs200914627027519516233
- NavaGMAttene-RamosMSAngJKEscorciaMOrigins of the new influenza A(H1N1) virus: time to take actionEuro Surveill20091422 pii:19228
- HaydenECAvian influenza aided readiness for swine fluNature2009459724875675719516303
- SilversidesASwine flu outbreak tests Canadian preparednessCMAJ200918012E93E9419506266
- Kuntz-SimonGMadecFGenetic and antigenic evolution of swine influenza viruses in Europe and evaluation of their zoonotic potentialZoonoses Public Health2009529 [Epub ahead of print]
- OpalSMSwine flu, pandemics, and critical careCrit Care200913314619490596
- CastledineGSwine flu panic is being spread by ignoranceBr J Nurs2009181065119491743
- MossadSBThe resurgence of swine-origin influenza A (H1N1)Cleve Clin J Med200976633734319487554
- CohenJSwine flu outbreak. New details on virus’s promiscuous pastScience20093245931112719478151
- ButlerDSwine flu attention turns to the tropicsNature2009459724649049119478748
- CollinNde RadiguèsXKienyMPthe World Health Organization H1N1 Vaccine Task ForceNew influenza A(H1N1) vaccine: How ready are we for large-scale production?Vaccine2009626 [Epub ahead of print]
- GartenRJDavisCTRussellCAAntigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humansScience2009325593719720119465683
- Couzin-FrankelJSwine flu outbreak. What role for antiviral drugs?Science2009324592870519423784
- Centers for Disease Control and Prevention (CDC)Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009MMWR Morb Mortal Wkly Rep2009581643343519407738
- Centers for Disease Control and Prevention (CDC)Update: swine influenza A (H1N1) infections – California and Texas, April 2009MMWR Morb Mortal Wkly Rep2009581643543719407739
- SchirmerPHolodniyMOseltamivir for treatment and prophylaxis of influenza infectionExpert Opin Drug Saf20098335737119355841
- WiwanitkitVAntiviral drug treatment for emerging swine fluClin Ther20091603243245
- DuQSWangSQHuangRBZhangDWChouKCInsights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virusBiochem Biophys Res Commun2009386343243619523442
- Maurer-StrohSMaJLeeRTSirotaFLEisenhaberFMapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sitesBiol Direct200941819457254
- EnserinkMKaiserJSwine flu outbreak. Devilish dilemmas surround pandemic flu vaccineScience2009324592870270519423782
- BarasBBouveretNDevasterJMA vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza virusesInfluenza Other Respi Viruses20082625126019453402
- SavilleMMarshGHoffenbachAImproving seasonal and pandemic influenza vaccinesInfluenza Other Respi Viruses20082622923519453399